Trial Profile
A Study of the Effect of Ascending Single Doses of DG3173 and 300 μg of Octreotide on Human Growth Hormone Levels in Untreated Acromegalics.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Veldoreotide (Primary) ; Octreotide
- Indications Acromegaly
- Focus Therapeutic Use
- Sponsors Aspireo Pharmaceuticals
- 19 Sep 2014 New trial record